These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 32481735)

  • 41. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
    Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Homologous recombination proficiency in ovarian and breast cancer patients.
    Creeden JF; Nanavaty NS; Einloth KR; Gillman CE; Stanbery L; Hamouda DM; Dworkin L; Nemunaitis J
    BMC Cancer; 2021 Oct; 21(1):1154. PubMed ID: 34711195
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical management of women with genomic BRCA1 and BRCA2 mutations.
    Chang J; Elledge RM
    Breast Cancer Res Treat; 2001 Sep; 69(2):101-13. PubMed ID: 11759816
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy.
    Santarosa M; Dolcetti R; Magri MD; Crivellari D; Tibiletti MG; Gallo A; Tumolo S; Della Puppa L; Furlan D; Boiocchi M; Viel A
    Int J Cancer; 1999 Sep; 83(1):5-9. PubMed ID: 10449599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
    Zhang F; Ma J; Wu J; Ye L; Cai H; Xia B; Yu X
    Curr Biol; 2009 Mar; 19(6):524-9. PubMed ID: 19268590
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BRCA1 and BRCA2 germline mutation spectrum in hereditary breast/ovarian cancer families from Maghrebian countries.
    Cherbal F; Bakour R; Adane S; Boualga K
    Breast Dis; 2012; 34(1):1-8. PubMed ID: 23697973
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.
    Einbeigi Z; Bergman A; Meis-Kindblom JM; Flodin A; Bjursell C; Martinsson T; Kindblom LG; Wahlström J; Wallgren A; Nordling M; Karlsson P
    Fam Cancer; 2007; 6(1):35-41. PubMed ID: 16944270
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
    Pothuri B
    Ann Oncol; 2013 Nov; 24 Suppl 8():viii22-viii27. PubMed ID: 24131965
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families.
    Claes K; Poppe B; Coene I; Paepe AD; Messiaen L
    Br J Cancer; 2004 Mar; 90(6):1244-51. PubMed ID: 15026808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Implication of BRCA1 gene in breast cancer.
    Kachhap SK; Ghosh SN
    Indian J Exp Biol; 2001 May; 39(5):391-400. PubMed ID: 11510120
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes.
    Pietragalla A; Arcieri M; Marchetti C; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2020 Nov; 30(11):1803-1810. PubMed ID: 32895312
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BRCA1 gene: function and deficiency.
    Takaoka M; Miki Y
    Int J Clin Oncol; 2018 Feb; 23(1):36-44. PubMed ID: 28884397
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
    Sung PL; Wen KC; Chen YJ; Chao TC; Tsai YF; Tseng LM; Qiu JT; Chao KC; Wu HH; Chuang CM; Wang PH; Huang CF
    PLoS One; 2017; 12(9):e0185615. PubMed ID: 28961279
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families.
    Peixoto A; Salgueiro N; Santos C; Varzim G; Rocha P; Soares MJ; Pereira D; Rodrigues H; Bento MJ; Fráguas A; Moura G; Regateiro F; Castedo S; Teixeira MR
    Fam Cancer; 2006; 5(4):379-87. PubMed ID: 16826315
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Homologous repair deficiency score for identifying breast cancers with defective DNA damage response.
    Min A; Kim K; Jeong K; Choi S; Kim S; Suh KJ; Lee KH; Kim S; Im SA
    Sci Rep; 2020 Jul; 10(1):12506. PubMed ID: 32719318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hereditary ovarian cancer.
    Prat J; Ribé A; Gallardo A
    Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers.
    Paul A; Paul S
    Front Biosci (Landmark Ed); 2014 Jan; 19(4):605-18. PubMed ID: 24389207
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
    George J; Alsop K; Etemadmoghadam D; Hondow H; Mikeska T; Dobrovic A; deFazio A; ; Smyth GK; Levine DA; Mitchell G; Bowtell DD
    Clin Cancer Res; 2013 Jul; 19(13):3474-84. PubMed ID: 23633455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.